Free Trial

Alnylam Pharmaceuticals (ALNY) Stock Forecast & Price Target

Alnylam Pharmaceuticals logo
$264.99 +18.72 (+7.60%)
As of 04:00 PM Eastern

Alnylam Pharmaceuticals - Analysts' Recommendations and Stock Price Forecast (2025)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Sell
1
Hold
5
Buy
19

Based on 25 Wall Street analysts who have issued ratings for Alnylam Pharmaceuticals in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 25 analysts, 1 has given a sell rating, 5 have given a hold rating, and 19 have given a buy rating for ALNY.

Consensus Price Target

$298.61
12.69% Upside
According to the 25 analysts' twelve-month price targets for Alnylam Pharmaceuticals, the average price target is $298.61. The highest price target for ALNY is $400.00, while the lowest price target for ALNY is $159.00. The average price target represents a forecasted upside of 12.69% from the current price of $264.99.
Get the Latest News and Ratings for ALNY and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Alnylam Pharmaceuticals and its competitors.

Sign Up

ALNY Analyst Ratings Over Time

TypeCurrent Forecast
1/22/24 to 1/21/25
1 Month Ago
12/23/23 to 12/22/24
3 Months Ago
10/24/23 to 10/23/24
1 Year Ago
1/22/23 to 1/22/24
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
19 Buy rating(s)
18 Buy rating(s)
18 Buy rating(s)
13 Buy rating(s)
Hold
5 Hold rating(s)
5 Hold rating(s)
6 Hold rating(s)
7 Hold rating(s)
Sell
1 Sell rating(s)
1 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$298.61$298.09$290.86$227.85
Forecasted Upside12.69% Upside21.45% Upside-1.36% Downside23.89% Upside
Consensus Rating
Moderate Buy
Moderate Buy
Moderate Buy
Moderate Buy

ALNY Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

ALNY Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Alnylam Pharmaceuticals Stock vs. The Competition

TypeAlnylam PharmaceuticalsMedical CompaniesS&P 500
Consensus Rating Score
2.72
2.82
2.52
Consensus RatingModerate BuyModerate BuyModerate Buy
Predicted Upside12.69% Upside24,935.86% Upside11.17% Upside
News Sentiment Rating
Positive News

See Recent ALNY News
Positive News
Positive News
DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
1/21/2025Royal Bank of Canada
4 of 5 stars
Luca Issi
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Outperform$300.00 ➝ $300.00+16.29%
1/13/2025HC Wainwright
2 of 5 stars
Patrick Trucchio
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$400.00 ➝ $400.00+60.26%
1/13/2025Needham & Company LLC
2 of 5 stars
Joseph Stringer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$320.00 ➝ $320.00+34.47%
1/7/2025Sanford C. Bernstein
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetOutperform ➝ Outperform$314.00 ➝ $310.00+31.53%
11/19/2024William Blair
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingOutperform
11/18/2024Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingOverweight ➝ Overweight$296.00 ➝ $296.00+27.70%
11/12/2024Wolfe Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
A. Chen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradePeer Perform ➝ Underperform
11/1/2024Raymond James
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOutperform ➝ Outperform$275.00 ➝ $298.00+10.74%
11/1/2024Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOverweight ➝ Overweight$295.00 ➝ $329.00+23.61%
11/1/2024Scotiabank
Subscribe to MarketBeat All Access for the recommendation accuracy rating
G. Harrison
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost TargetSector Outperform ➝ Sector Outperform$305.00 ➝ $310.00+16.48%
11/1/2024Canaccord Genuity Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy ➝ Buy$366.00 ➝ $384.00+44.04%
11/1/2024Chardan Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingBuy ➝ Buy$300.00 ➝ $300.00+12.53%
10/21/2024TD Cowen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy ➝ Buy$282.00 ➝ $371.00+25.37%
10/14/2024Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy ➝ Buy$307.00 ➝ $314.00+10.70%
10/11/2024Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingNeutral ➝ Neutral$220.00 ➝ $220.00-21.77%
8/26/2024JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetNeutral ➝ Neutral$248.00 ➝ $280.00+3.37%
8/16/2024The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
S. Richter
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeNeutral ➝ Buy$198.00 ➝ $370.00+40.85%
8/2/2024Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetEqual Weight ➝ Equal Weight$207.00 ➝ $233.00-14.17%
8/2/2024Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy ➝ Buy$291.00 ➝ $342.00+24.91%
7/12/2024Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetEqual Weight ➝ Equal Weight$250.00 ➝ $255.00-3.04%
6/28/2024UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
E. Merle
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost TargetBuy ➝ Buy$253.00 ➝ $288.00+18.37%
6/27/2024Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy ➝ Buy$215.00 ➝ $295.00+20.32%
6/25/2024Leerink Partners
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetMarket Perform ➝ Market Perform$138.00 ➝ $159.00-33.15%
6/25/2024Evercore ISI
Subscribe to MarketBeat All Access for the recommendation accuracy rating
L. Bayko
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost TargetOutperform ➝ Outperform$210.00 ➝ $260.00+12.40%
6/24/2024BMO Capital Markets
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingOutperform ➝ Outperform$234.00 ➝ $234.00+3.28%
10/11/2023Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeOutperform ➝ Market Perform
4/26/2023Sumitomo Mitsui Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageNeutral$220.00+8.83%
2/21/2023EF Hutton Acquisition Co. I
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageBuy$304.00+48.68%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Tuesday at 11:33 PM ET.


Should I Buy Alnylam Pharmaceuticals Stock? ALNY Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Tuesday, January 7, 2025. Please send any questions or comments about these Alnylam Pharmaceuticals pros and cons to contact@marketbeat.com.

Alnylam Pharmaceuticals
Bull Case

green Wall Street bull icon

Here are some ways that investors could benefit from investing in Alnylam Pharmaceuticals, Inc.:

  • Alnylam Pharmaceuticals, Inc. has recently been upgraded to a "buy" rating by analysts, indicating strong confidence in the company's future performance.
  • The stock price is currently at $237.92, which reflects a significant increase of 65% in recent trading sessions, suggesting positive market sentiment.
  • Analysts have set a consensus target price of $298.09, which indicates potential upside for investors based on current trading levels.
  • The company has a robust pipeline focused on novel therapeutics based on ribonucleic acid interference, which positions it well in the biopharmaceutical sector.
  • Institutional investors hold a substantial 92.97% of the company's stock, indicating strong institutional confidence and support for Alnylam Pharmaceuticals, Inc.

Alnylam Pharmaceuticals
Bear Case

red Wall Street bear icon

Investors should be bearish about investing in Alnylam Pharmaceuticals, Inc. for these reasons:

  • The company reported a loss of ($0.87) earnings per share (EPS), which was significantly below the consensus estimate of ($0.51), raising concerns about profitability.
  • Quarterly revenue decreased by 33.3% compared to the same quarter last year, indicating potential challenges in maintaining sales growth.
  • Despite the positive stock performance, one analyst has rated the stock with a sell rating, suggesting that not all market participants are optimistic about its future.
  • Insider selling activity has been noted, with executives selling shares, which could signal a lack of confidence in the company's short-term prospects.
  • The company has a high debt-to-equity ratio of 31.64, which may raise concerns about financial stability and the ability to manage debt effectively.

ALNY Forecast - Frequently Asked Questions

According to the research reports of 25 Wall Street equities research analysts, the average twelve-month stock price forecast for Alnylam Pharmaceuticals is $298.61, with a high forecast of $400.00 and a low forecast of $159.00.

25 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Alnylam Pharmaceuticals in the last year. There is currently 1 sell rating, 5 hold ratings and 19 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" ALNY shares.

According to analysts, Alnylam Pharmaceuticals's stock has a predicted upside of 12.69% based on their 12-month stock forecasts.

Over the previous 90 days, Alnylam Pharmaceuticals's stock had 1 downgrade by analysts.

Analysts like Alnylam Pharmaceuticals less than other "medical" companies. The consensus rating score for Alnylam Pharmaceuticals is 2.72 while the average consensus rating score for "medical" companies is 2.82. Learn more on how ALNY compares to other companies.


This page (NASDAQ:ALNY) was last updated on 1/21/2025 by MarketBeat.com Staff
From Our Partners